A Multiple-Center, Randomized, Double-Blind, Placebo-Controlled, Single-Ascending Dose and Multiple-Ascending Dose, Adaptive Parallel Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RO7020322 Following Oral Administration in Healthy Subjects and Chronic Hepatitis B Patients
Phase of Trial: Phase I
Latest Information Update: 30 May 2017
At a glance
- Drugs RG 7834 (Primary)
- Indications Hepatitis B
- Focus Adverse reactions
- Sponsors Roche
- 23 May 2017 Status changed from recruiting to discontinued.
- 01 Jun 2016 Planned End Date changed from 1 Mar 2017 to 1 Apr 2017.
- 01 Jun 2016 Planned primary completion date changed from 1 Mar 2017 to 1 Apr 2017.